Design and evaluation of cyclodextrin-based delivery systems to incorporate poorly soluble curcumin analogs for the treatment of melanoma

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 81, Issue 3, 2012, Pages 548-556

  Michel, Deborah ^a   Chitanda, Jackson M ^a   Balogh, Réka ^b   Yang, Peng ^c   Singh, Jagbir ^a   Das, Umashankar ^a   El Aneed, Anas ^a   Dimmock, Jonathan ^a   Verrall, Ronald ^a   Badea, Ildiko ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Curcumin analogs; Cyclodextrin derivatives; Cytotoxic nanoparticles; Gemini surfactants; Melanoma; Selective cytotoxicity

Indexed keywords

1,5 DIARYL 3 OXO 1,4 PENTADIENYL; BETA CYCLODEXTRIN; CURCUMIN; MELPHALAN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; MELANOMA; PARTICLE SIZE; ZETA POTENTIAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA-CYCLODEXTRINS; CELL LINE, TUMOR; CURCUMIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; INHIBITORY CONCENTRATION 50; KERATINOCYTES; MELANOMA; NANOPARTICLES; PARTICLE SIZE; QUATERNARY AMMONIUM COMPOUNDS; SOLUBILITY;

EID: 84863777820     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.03.016     Document Type: Article

References (40)

1. D. Vetvicka, M. Hruby, O. Hovorka, et al., Biological evaluation of polymeric micelles with covalently bound doxorubicin, Bioconjug. Chem. 20 (2009) 2090-2097.
2. X.J. Liang, C. Chen, Y. Zhao, et al., Circumventing tumor resistance to chemotherapy by nanotechnology, Methods Mol. Biol. 596 (2010) 467-488.
3. J. Padsis, R. Turley, D. Tyler, Pharmacotherapy of regional melanoma therapy, Exp. Opin. Pharmacother. 11 (2010) 79-93.
4. I. Badea, R. Verrall, M. Baca-Estrada, et al., In vivo cutaneous interferon-gamma gene delivery using novel dicationic (gemini) surfactant-plasmid complexes, J. Gene Med. 7 (2005) 1200-1214. (Pubitemid 41335172)
5. I. Badea, C. Virtanen, R.E. Verrall, et al., Effect of topical interferon-gamma gene therapy using gemini nanoparticles on pathophysiological markers of cutaneous scleroderma in Tsk/+ mice, Gene Ther. (2011), http://dx.doi.org/10.1038/gt.2011.159.
6. I. Badea, S. Wettig, R. Verrall, et al., Topical non-invasive gene delivery using gemini nanoparticles in interferon-gamma-deficient mice, Eur. J. Pharm. Biopharm. 65 (2007) 414-422.
7. U. Das, J. Alcorn, A. Shrivastav, et al., Design, synthesis and cytotoxic properties of novel 1-[4-(2-alkylaminoethoxy)phenylcarbonyl]-3,5-bis(arylidene) -4-piperidones and related compounds, Eur. J. Med. Chem. 42 (2007) 71-80. (Pubitemid 46198985)
8. J.R. Dimmock, S.K. Raghavan, B.M. Logan, et al., Anti-leukemic evaluation of some Mannich-bases derived from 2-arylidene-1,3-diketones, Eur. J. Med. Chem. 18 (1983) 248-254. (Pubitemid 13069181)
9. B. Mutus, J.D. Wagner, C.J. Talpas, et al., 1-Para-chlorophenyl-4,4- dimethyl-5-diethylamino-1-penten-3-one hydrobromide, a sulfhydryl-specific compound which reacts irreversibly with protein thiols but reversibly with small molecular-weight thiols, Anal. Biochem. 177 (1989) 237-243. (Pubitemid 19088252)
10. U. Das, H. Sakagami, Q. Chu, et al., 3,5-Bis(benzylidene)-1-[4-2- (morpholin-4-yl)ethoxyphenylcarbonyl]-4-piperidone hydrochloride: a lead tumor-specific cytotoxin which induces apoptosis and autophagy, Bioorg. Med. Chem. Lett. 20 (2010) 912-917.
11. U. Das, P. Selvakumar, R.K. Sharma, et al., N-acyl-3,5-bis(arylidene)-4- piperidones and related compounds which stimulate fyn kinase, J. Enzyme Inhib. Med. Chem. 22 (2007) 451-455. (Pubitemid 47225708)
12. J.R. Dimmock, U. Das, S. Das, et al., N-Aroyl-3,5-bis(benzylidene)-4- piperidones: a novel class of antimycobacterial agents, Bioorg. Med. Chem. 16 (2008) 3602-3607. (Pubitemid 351484043)
13. H.J. Doh, W.J. Cho, C.S. Yong, et al., Synthesis and evaluation of Ketorolac ester prodrugs for transdermal delivery, J. Pharm. Sci. 92 (2003) 1008-1017.
14. C. Li, L. Nair, T. Liu, et al., Correlation between PAMPA permeability and cellular activities of hepatitis C virus protease inhibitors, Biochem. Pharmacol. 75 (2008) 1186-1197.
15. V. Tantishaiyakul, K. Wiwattanawongsa, S. Pinsuwan, et al., Characterization of mefenamic acid-guaiacol ester: stability and transport across Caco-2 cell monolayers, Pharm. Res. 19 (2002) 1013-1018. (Pubitemid 34804244)
16. J. Parkin, C. Shea, G.R. Sant, Intravesical dimethyl sulfoxide (DMSO) for interstitial cystitis - a practical approach, Urology 49 (1997) 105-107. (Pubitemid 27193960)
17. V.R. Yadav, S. Prasad, R. Kannappan, et al., Cyclodextrin-complexed curcumin exhibits anti-inflammatory and antiproliferative activities superior to those of curcumin through higher cellular uptake, Biochem. Pharmacol. 80 (2010) 1021-1032.
18. M.M. Yallapu, M. Jaggi, S.C. Chauhan, Beta-cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells, Colloids Surf. B Biointerfaces 79 (2010) 113-125.
19. R. Challa, A. Ahuja, J. Ali, et al., Cyclodextrins in drug delivery: an updated review, AAPS PharmSciTech. 6 (2005). E329-357.
20. F.M. Menger, J.S. Keiper, Gemini surfactants, Angew. Chem. Int. Ed. Engl. 39 (2000) 1906-1920. (Pubitemid 30399120)
21. S.D. Wettig, I. Badea, M. Donkuru, et al., Structural and transfection properties of amine-substituted gemini surfactant-based nanoparticles, J. Gene Med. 9 (2007) 649-658. (Pubitemid 47288823)
22. P. Yang, J. Singh, S. Wettig, et al., Enhanced gene expression in epithelial cells transfected with amino acid-substituted gemini nanoparticles, Eur. J. Pharm. Biopharm. 75 (2010) 311-320.
23. I. Badea, S. Babiuk, L. Babiuk, et al., Gemini nanoparticles as immunomodulatory and co-delivery system for antigen-CpG oligodeoxynucleotide adjuvant combination, Int. J. Biomed. Nanosci. Nanotechnol. 1 (2011) 290-307.
24. H.S. Rosenzweig, V.A. Rakhmanova, R.C. MacDonald, Diquaternary ammonium compounds as transfection agents, Bioconjug. Chem. 12 (2001) 258-263. (Pubitemid 32235478)
25. J.B. Huang, D.F. Yu, X. Huang, et al., Effects of inorganic and organic salts on aggregation behavior of cationic gemini surfactants, J. Phys. Chem. B 114 (2010) 14955-14964.
26. X. Du, X. Chen, W. Lu, et al., Spectroscopic study on binding behaviors of different structural nonionic surfactants to cyclodextrins, J. Colloid Interface Sci. 274 (2004) 645-651. (Pubitemid 38610338)
27. R.S.Y. Wong, Apoptosis in cancer: from pathogenesis to treatment, J. Exp. Clin. Cancer Res. 30 (2011).
28. S. Bhatia, S.S. Tykodi, J.A. Thompson, Treatment of metastatic melanoma: an overview, Oncology (Williston Park) 23 (2009) 488-496.
29. E.C. Dreaden, S.C. Mwakwari, Q.H. Sodji, et al., Tamoxifen-poly(ethylene glycol)-thiol gold nanoparticle conjugates: enhanced potency and selective delivery for breast cancer treatment, Bioconjug. Chem. 20 (2009) 2247-2253.
30. M. Foldvari, I. Badea, S. Wettig, et al., Structural characterization of novel gemini non-viral DNA delivery systems for cutaneous gene therapy, J. Exp. Nanosci. 1 (2006) 165-176.
31. C.M. Hu, L. Zhang, Therapeutic nanoparticles to combat cancer drug resistance, Curr. Drug Metab. 10 (2009) 836-841.
32. C.A. Ventura, I. Giannone, T. Musumeci, et al., Physico-chemical characterization of disoxaril-dimethyl-beta-cyclodextrin inclusion complex and in vitro permeation studies, Eur. J. Med. Chem. 41 (2006) 233-240.
33. P. Anand, H.B. Nair, B. Sung, et al., Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo, Biochem. Pharmacol. 79 (2010) 330-338.
34. R. Singh, H.H. Tonnesen, S.B. Vogensen, et al., Studies of curcumin and curcuminoids. XXXVI. The stoichiometry and complexation constants of cyclodextrin complexes as determined by the phase-solubility method and UV-Vis titration, J. Incl. Phenom. Macrocy. Chem. 66 (2010) 335-348.
35. G. Sa, T. Das, Anticancer effects of curcumin: cycle of life and death, Cell Div. 3 (2008) 14.
36. J. McGrath, R. Eady, F. Pope, Anatomy and organization of human skin, in: T. Burns, S. Breathnach, N. Cox, C. Griffiths (Eds.), Rook's Textbook of Dermatology, seventh ed., Blackwell Publishing, 2004, p. 1490.
37. S. Mittal, X. Song, B.S. Vig, et al., Proline prodrug of melphalan targeted to prolidase, a prodrug activating enzyme overexpressed in melanoma, Pharm. Res. 24 (2007) 1290-1298. (Pubitemid 46870594)
38. C.J. Sherr, F. McCormick, The RB and p53 pathways in cancer, Cancer Cell 2 (2002) 103-112. (Pubitemid 41039110)
39. J.A. Bush, K.J. Cheung Jr., G. Li, Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53, Exp. Cell Res. 271 (2001) 305-314. (Pubitemid 33141212)
40. J. Singh, P. Yang, D. Michel, et al., Amino acid-substituted gemini surfactant-based nanoparticles as safe and versatile gene delivery agents, Curr. Drug Deliv. 8 (2011) 299-306.